Dr. Mario Cioce
Faculty of Medicine and Surgery, University Campus-Biomedico, Rome, Italy.
Dr. Maria Rosaria De Miglio
Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
Special Issue Introduction
Resistance to therapy is major challenge of the clinical management of cancer patients. Recent approaches have shown how intra-tumoral heterogeneity (ITH) is a major propeller of drug resistance, because of the clonal evolution and the consequent broad spectrum of stress- adaptive mechanisms set in place in therapy-challenged tumors. Omics approaches, including transcriptomic, genomic, proteomics and metabolomics analysis and targeted at both cancer cells and tumor microenvironment, are expected to greatly contribute knowledge of resistance mechanisms to overcome such a challenge. Another critical point is the choice of relevant sources and experimental settings to study resistance to therapy. This broadly covers in vitro cell culturing up to 3D cultures and organoids, with the last two holding more promise due to the ability to keep a more intact genetic makeup of the originating specimen. Current efforts to overcome cancer drug resistance do need to consider, on one hand, the high need for novel agents and, on the other hand, potential for drug repositioning and sequencing of treatments. This requires a tighter than ever interaction between basic, translational and clinical scientist and to this interdisciplinary audience is devoted this Special Issue of Cancer Drug Resistance.
Signaling pathways, targeted therapies, single-cell biology, nanomedicines, precision oncology, omics, drug resistance, cancer stem cells, epithelial mesenchymal transition, metabolism, tumor microenvironment
31 Mar 2022